AstraZeneca’s COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes

The full data reinforces hopes that the drug could be a breakthrough COPD treatment and reach AstraZeneca’s peak annual sales forecast of more than $5 billion.

The full data reinforces hopes that the drug could be a breakthrough COPD treatment and reach AstraZeneca’s peak annual sales forecast of more than $5 billion.

About the Author

Leave a Reply

Your email address will not be published. Required fields are marked *

About the Author

Easy WordPress Websites Builder: Versatile Demos for Blogs, News, eCommerce and More – One-Click Import, No Coding! 1000+ Ready-made Templates for Stunning Newspaper, Magazine, Blog, and Publishing Websites.

BlockSpare — News, Magazine and Blog Addons for (Gutenberg) Block Editor

Search the Archives

Access over the years of investigative journalism and breaking reports